脂蛋白(a)与动脉粥样硬化研究进展

Advances in Relationship Between Lipoprotein(a) and Atherosclerosis

脂蛋白(a)由低密度脂蛋白和载脂蛋白(a)组成。高血浆脂蛋白(a)水平是动脉粥样硬化和心血管疾病的独立危险因素。脂蛋白(a)不但能参与动脉粥样硬化斑块的形成,还能影响抗炎机制和血管壁中促凝与抗凝因子的平衡。血浆脂蛋白(a)水平的个体差异很大,主要受遗传因素控制。血浆脂蛋白(a)水平对药理和非药理因素都不敏感,临床上缺乏高效安全降低脂蛋白(a)水平的治疗方法。近年,科研工作者发现反义寡核苷酸链和人工合成的肽链等可以降低脂蛋白(a)水平,但用于临床治疗还需进一步研究。本文拟对近年来脂蛋白(a)与动脉粥样硬化研究的新进展进行综述。

Lipoprotein （a） consists of low density lipoprotein （LDL） and the unique constituent apolipoprotein （a）. Elevated plasma lipoprotein （a） level is an independent risk factor of atherosclerotic disorders and cardiovascular dis- ease. Lipoprotein（a） not only can participate in the formation of atheromatous plaque but also affect the anti-inflammatory mechanism and the balance between procoagulant and anticoagulant agents of the blood vessel wall. Plasma lipoprotein （a） levels which are under strong genetic control can be quite different between individuals. Lipoprotein（a） plasma lev- els are relatively resistant to many pharmacologic and nonpharmacologic agents, effective and safe approaches to lower Lipo- protein（a） plasma level in clinic are still lacking. However, in recent years, researchers have found a few methods to lower lipoprotein（a） level in laboratory, such as antisense oligonucleotides and synthetic peptides, but further researches are needed when use them as new therapic methods. This paper reviewed the recent research advances in relationship be- tween lipoprotein（a） and atherosclerosis.